Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)

Roivant chops sick­le cell gene ther­a­py, der­ma­tol­ogy drugs to fo­cus on 'high­er val­ue pro­ject­s'

Roivant is sweep­ing a suite of drugs, in­clud­ing a gene ther­a­py for sick­le cell dis­ease al­ready in the clin­ic, out of its pipeline.

Six pro­grams from four of its “vants” are be­ing wound down as part of “a com­pa­ny-wide cost op­ti­miza­tion and pipeline repri­or­i­ti­za­tion ini­tia­tive to re­duce our ex­pect­ed op­er­at­ing ex­pens­es and pri­or­i­tize our cap­i­tal re­sources.”

When reached by End­points News, a spokesper­son said, “We don’t an­tic­i­pate a ma­te­r­i­al re­duc­tion in head­count but we will like­ly re­as­sign some folks to high­er val­ue projects as part of wind­ing down spe­cif­ic pro­grams.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.